

FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 1E




FIG. 2A




FIG. 2B




FIG. 2C





FIG. 2D


	IFN gamma release Emax (pg/mL)	IFN gamma release EC50 (pM)	IFN gamma release AUC
anti-HEL	N/A	N/A	N/A
Fuse-691	1142	~5000-8000	109143464
Fuse-774	1668	~5000-8000	266170384
Fuse-694	1946	>5000	165015835
Fuse-765	2780	~5000-8000	251235285
Fuse-773	2612	>5000	213768621
Fuse-774 + Fuse-694 (1:1)	7427	~3000	677275434
Fuse-765 + Fuse-694 (1:1)	11484	~3000	1004042426
Fuse-773 + Fuse-694 (1:1)	12924	~3000	1151326789



	anti-HEL	Fuse-691	Fuse-694	Fuse-696	Fuse-697
IFN gamma release Emax (pg/mL)	NA	831	2002	9061	21679
IFN gamma release EC50 (pM)	NA	~5000-8000	~5000-8000	5354	174
IFN gamma release AUC	0	77593970	167007827	797028870	2094273460


FIG. 3

FIG. 4A



	anti-HEL	Fuse-916	Fuse-923	Fuse-926
Killing Emax (%)	N/A	88.52	50.11	56.46
Killing EC50 (pM)	N/A	1656	14577	8785
Killing AUC	2613812	7908745	4051901	4848033

FIG. 4B



	anti-HEL	Fuse-916	Fuse-923	Fuse-926
IFNG release Emax (pg/mL)		1180	624.4	171.9
IFNG release EC50 (pM)		~3000	>30,000	>30,000
IFNG release AUC	4727938	90626898	36217143	12810957




FIG. 5A




FIG. 5B




FIG. 6A




FIG. 6B




FIG. 7A




FIG. 7B

FIG. 8A




FIG. 8B




FIG. 9A




FIG. 9B NK fold frequency from PBMCs-21 days




FIG. 9C NK fold expansion from PBMCs-21 days






FIG. 10A




	anti-HEL	Fuse-1062	Fuse-1063	Fuse-1065	Fuse-1072	Fuse-1074	Fuse-1075	Fuse-1078
Killing Emax (%)	5.013	75.22	87.56	79.41	84.61	75.62	71.97	1388
Killing EC50 (pM)	Unstable	178.4	45.48	73.48	27.45	95.22	1374	Unstable
Killing AUC	3947286	60017451	69919179	62791550	67494375	60916056	55960573	8091733

FIG. 10B




	anti-HEL	Fuse-1064	Fuse-1072	Fuse-1073	Fuse-1076	Fuse-1077	Fuse-1078
Killing Emax (%)	5.769	72.18	84.06	61.67	41.9	68.99	19.47
Killing EC50 (pM)	Unstable	203.8	55.67	887.7	2440	713.2	91952
Killing AUC	4580287	57459609	66451796	48251341	32229201	53970025	11440617



	anti-HEL	Fuse-1136	Fuse-1137	Fuse-1138	Fuse-1139
Killing Emax (%)	5.907	77.65	69.28	60.74	54.29
Killing EC50 (pM)	Unstable	38.93	68.73	147.3	165.9
Killing AUC	727241	7596205	6881847	5985196	5293896

FIG. 11B


IFN-gamma release



	anti-HEL	Fuse-1136	Fuse-1137	Fuse-1138	Fuse-1139
IFN gamma release Emax (pg/mL)	0	9698	Unstable	305.6	157.8
IFN gamma release EC50 (pM)	Unstable	3448	Unstable	368.2	16.78
IFN gamma release AUC	0	851195375	191263791	28371126	14959383

FIG. 12A

NK cell and P815 eGFP FLUC cell 24-hour cytotoxicity assay




	anti-HEL	Fuse-745	Fuse-746	Fuse-747	Fuse-748	Fuse-749	Fuse-750	Fuse-751	Fuse-752	Fuse-753
killing Emax (%)	NA	10.41	10.51	12.19	61.29	54.01	55.65	38.25	43.15	29.89
killing EC50 (pM)	NA	~ 175.2	~ 672.3	2382	44.96	57.5	44.7	155.4	181.5	131.4
Killing AUC	37.06	42.64	44.35	44.22	211.2	183.3	189.3	124.2	132.9	97.3

	anti-HEL	anti-NKP46 461-G1	anti-NKP46 D2-9A5	Fuse-739	Fuse-740	Fuse-741	Fuse-742	Fuse-743	Fuse-744
killing Emax (%)	NA	35.8	43.91	33.91	30.82	30.94	19.8	23.54	17.04
killing EC50 (pM)	NA	68.66	60.74	72.64	132.8	76.86	74.33	108	83.22
Killing AUC	37.06	123.5	151.5	115.9	103.3	106.1	74.05	84.25	64.82

FIG. 12B


NK cell and P815 eGFP FLUC cell 24-hour cytotoxicity assay



	anti-HEL	mouse anti-human NKP46 (D2-9A5)	Fuse-748	4D6	4C9	5E10
killing Emax		34.02	45.06	57.39	53.51	38.79
Killing EC50 (pM)		81.45	65.32	100.2	139.3	202.4
Killing AUC	9068622	26692890	35186226	45024531	41548642	30010002

	3H8	3F8	2C8	5E7	3A6	1B8	5B9
killing Emax	42.38	41.05	33.63	36.77	28.49	20.28	33.91
Killing EC50 (pM)	236.2	194.8	5173	587.8	4964	1301	1388
Killing AUC	33252883	31768925	22458026	28958187	21732669	16267010	26516301

FIG. 12C
NK cell and P815 eGFP FLUC cell 24-hour cytotoxicity assay



	anti-HEL	Fuse-1054	Fuse-1128	Fuse-1129	Fuse-1130	Fuse-1184
Killing Emax (%)		78.46	74.47	88.61	66.59	62.79
Killing EC50 (pM)		9.747	17.16	2.236	7.372	45.01
Killing AUC	17164271	62317545	59208493	70220735	52128179	49591888

FIG. 13A

Expanded NK cells and Jurkat eGFP ROR1 cell 72-hr killing and IFN
gamma release at E:T of 3:1





FIG. 13B

IFN-gamma release







FIG. 16






FIG. 17A



	hIL-15	Fuse-691	Fuse-696	Fuse-764	Fuse-765
Emax (OD at 630nM)	1.752	0.05988	2.037	1.931	1.666
EC50 (pM)	3.395	NA	178.8	183.3	81.34
AUC	1720	NA	324844	312797	266683

	Fuse-766	Fuse-767	Fuse-768	Fuse-772	Fuse-773	Fuse-774
Emax (OD at 630nM)	1.727	1.803	1.818	1.916	2.043	1.72
EC50 (pM)	58.31	54.76	37.27	123.2	6290	14265
AUC	274785	287738	289260	303421	261799	197265


FIG. 17B



	hIL-15	Fuse-691	Fuse-773	Fuse-774	Fuse-803
Emax (OD at 630 nm)	1.742	0.05391	1.899	1.766	1.494
EC50 (pM)	3.874	NA	10557	18601	5675
AUC	1695	8746	222109	191340	202049

	Fuse-804	Fuse-846	Fuse-847	Fuse-848	Fuse-854
Emax (OD at 630 nm)	1.592	1.856	94.42	0.04698	1.714
EC50 (pM)	393.1	18999	~200000	NA	185.3
AUC	250625	197963	23064	7542	272783


FIG. 17C



	hIL-15	Fuse-691	Fuse-773
Emax (OD at 630 nm)	2.295	0.06107	2.536
EC50 (pM)	3.11	NA	12738
AUC	2266	9327	280248


	Fuse-846	Fuse-849	Fuse-850	Fuse-853
Emax (OD at 630 nm)	1.702	2.153	0.1242	2.208
EC50 (pM)	6112	164959	29568	2417
AUC	230144	109720	15112	333721

FIG. 18A




	anti-HEL	Fuse-691	Fuse-696
IFN gamma release Emax (pg/mL)	NA	853.6	9391
IFN gamma release EC50 (pM)	NA	2457	5354
IFN gamma release AUC	NA	77593970	797028870

FIG. 18B



	IL-15	anti-HEL	Fuse-691	Fuse-765	Fuse-773	Fuse-774
IFN gamma release Emax (pg/mL)	2784	NA	1127	3303	158687	1805
IFN gamma release EC50 (pM)	565.8	NA	2012	~4000	~8000	~10000
IFN gamma release AUC	263592876	NA	109143464	251235285	213768621	148625195

FIG. 19



		anti-HEL	Fuse-691	Fuse-696
96-hour IFNG release (T cell with DC)	IFN gamma release Emax (pg/mL)	NA	80921	212403
	IFN gamma release E50 (pM)	NA	9225	6475
	IFN gamma release AUC	23011	108924	288722
96-hour IFNG release (T cell alone)	IFN gamma release Emax (pg/mL)	NA	NA	NA
	IFN gamma release E50 (pM)	NA	NA	NA
	IFN gamma release AUC	8201	3450	1110
96-hour IFNG release (DC alone)	IFN gamma release Emax (pg/mL)	NA	NA	6892
	IFN gamma release E50 (pM)	NA	NA	3404
	IFN gamma release AUC	10555	9819	10671




FIG. 20A



FIG. 20B




FIG. 20C




FIG. 20D




FIG. 20E




FIG. 20F




FIG. 20G




FIG. 20H




FIG. 20I




FIG. 20J




FIG. 20K




FIG. 20L




FIG. 20M

FIG. 21A




FIG. 21B




FIG. 22A






FIG. 22B





	IL-18	FUSE645	FUSE691	FUSE694
EC50	~100	~10,000	~5000	~500
Max	11,529	1,826	2,718	7,595

FIG. 23




FIG. 24A




FIG. 24B




FIG. 25A






FIG. 25B




	anti-HEL	FUSE516	FUSE556	FUSE658	FUSE659	FUSE660
EC50	NA	105	>90000	391.5	53.05	46.61
Max	833.2	83.35	78.38	58.20	71.02	98.33

FIG. 26A



	anti-HEL	FUSE516	FUSE556	FUSE627
EC50	NA	367.1	>90,000	>270,000
Max	-0.3739	83.01	97.09	9.5

FIG. 26B








FIG. 27B










FIG. 30



	anti-HEL	Atez	Fuse-882	Fuse-895
IFNg Emax (%)	318.1	751.5	3351	3044
IFNg EC50 (pM)	0.5504	2593	>10,000	876.1
IFNg AUC	3.2E+07	71317675	1.09E+08	2.92E+08




	anti-HEL	Fuse-783	Fuse-1041	Fuse-1042	Fuse-1044	Fuse-1015
Killing Emax (%)		84.83	49.35	87.52	94.77	37.01
Killing EC50 (pM)		4645	5813	4031	2171	6088
Killing AUC	2194985	7344089	4337316	7547916	8662867	3392542



	anti-HEL	Fuse-783	Fuse-1041	Fuse-1042	Fuse-1044	Fuse-1015
IFN gamma release Emax (pg/mL)	223.2	3565	455.8	3725	4896	648.9
IFN gamma release EC50 (pM)	Unstable	5398	12697	2213	1280	18429
IFN gamma release AUC	22390830	2.92E+08	38837375	3.47E+08	4.75E+08	47693103


FIG. 32

HEK-Blue IL-18 mediated SEAP release




Group	EC50(pg/ml)
TNF-α	N/A
Human IL18	7.22
FUSE832	5.87
FUSE1109	1448.00
FUSE1110	N/A
FUSE1111	4492.00
FUSE1112	3841.00
FUSE1116	104.40

FIG. 33A
T cell mediated IFN γ release



	anti-HEL	hIL-18	Fuse-1017	Fuse-1109	Fuse-1110	Fuse-1111	Fuse-1112	Fuse-1116
IFN gamma release Emax (pg/mL)	N/A	8582	14573	11448	2288	9457	9556	18583
IFN gamma release EC50 (pM)	N/A	216.5	217.3	1509	6826	3794	2353	233.1

FIG. 33B



	Anti-HEL	Fuse-691	Fuse-1042	Fuse-1044	Fuse-1177	Fuse-1017
IFN gamma release Emax (pg/mL)	N/A	474.2	1417	2033	1210	2899
IFN gamma release EC50 (pM)	N/A	1027	2271	1584	1616	54.31

FIG. 34A

B16-F10.R TGI




FIG. 34B

SB16.F10.R Body weight




FIG. 34C




FIG. 34D




FIG. 35A





FIG. 35B







FIG. 37A




FIG. 37B




FIG. 38




FIG. 39





FIG. 40




FIG. 41






FIG. 42A



	anti-HEL	Fuse-599	Fuse-1109	Fuse-1177	Fuse-1179	Fuse-1229
Donor 1	517.8	11464	10340	3352	2315	2700
	Unstable	38.25	1466	1623	1107	1103
	51888316	1141189912	951020307	304812329	220634141	258063018

FIG. 42B



	anti-HEL	Fuse-599	Fuse-1109	Fuse-1177	Fuse-1179	Fuse-1229
Donor 2	Unstable	5825	5576	2791	2077	2513
	1.251	34.15	1042	1402	2175	1667
	31673165	576620139	517032308	250864165	185340564	226671174




FIG. 43




FIG. 44





FIG. 45



D

Compound	EC50-SEAP
Human rIL-18	0.0020 ng/ml
Human rTNFα	N/A
FUSE424	> 1000 ng/ml
FUSE424+EK	0.0011 ng/ml
FUSE441	> 1000 ng/ml
FUSE441+EK	0.022 ng/ml

FIG. 46




FIG. 47




FIG. 48




FIG. 49

FIG. 50






FIG .50

D

Compound	EC50-SEAP
Human rIL-18	0.01 ng/ml
Human rTNFα	N/A
FUSE499	>500 ng/ml
FUSE499 + Casp1	~0.01 ng/ml
FUSE500	~0.01 ng/ml
FUSE500 + Casp1	~0.01 ng/ml






Compound	EC50-SEAP
Human rIL-18	0.02 ng/ml
Human rTNFα	N/A
FUSE486	~33 ng/ml
FUSE486 + MMP2	~0.06 ng/ml
FUSE487	~100 ng/ml
FUSE487 + MMP2	~0.12 ng/ml

FIG. 51B

FIG. 51C



Compound	EC50-SEAP
Human rIL-18	1.38
Human rTNFα	N/A
FUSE587	3483
FUSE587 + MMP2	2.23
FUSE587 + Granzyme B	56.24




FIG. 51D




FIG. 51F

Compound.	EC50-SEAP
Human rIL-18	0.0020 ng/ml
Human rTNFα	N/A
FUSE462	>500 ng/ml
FUSE462 + GzmB	~0.03 ng/ml
FUSE485	>500 ng/ml
FUSE485 + GzmB	~0.03 ng/ml




FIG. 51G




FIG. 51I

Compound	EC50-SEAP
Human rIL-18	0.002 ng/ml
Human rTNFα	N/A
FUSE517	>500 ng/ml
FUSE517 + GzmB	~0.03 ng/ml





FIG. 52



	mut2	mut3	mut4	mut5	mut6	mut7	mut8	mut9	mut10	mut11	mut12
Fuse-500 (wt-AV)	Fuse-545	Fuse-546	Fuse-547	Fuse-583	Fuse-584	Fuse-585	Fuse-586	Fuse-599	Fuse-600	Fuse-601	Fuse-602
E42	-	K	R	A	H	R	Q	K	K		
M87	K	-	-					H	K	H	K
K89	G	G	G	A	G	E	A	G	G	A	A
M96	L	-	-					-	-	I	I
M149	V	-	-					-	-	I	I

FIG. 54A

	IL-18*	FUSE 500	FUSE 545	FUSE 546	FUSE 547	FUSE 583	FUSE 584	FUSE 585	FUSE 586	FUSE 599	FUSE 600	FUSE 601	FUSE 602
IL-18 BP Kd (nM)	4.00E-10	7.28E-10*	-	1.40E-07	4.00E-08	3.20E-09	4.00E-08	1.50E-07	2.60E-09	-	-	-	-

*<https://www.pnas.org/doi/10.1073/pnas.97.3.1190>

FIG. 54C

	IL18*	FUSE 500	FUSE 545	FUSE 546	FUSE 547	FUSE 583	FUSE 584	FUSE 585	FUSE 586	FUSE 599	FUSE 600	FUSE 601	FUSE 602
IL-18RA Kd (nM)	2E-08*	7.4E-09**	1.90E-08	1.80E-08	2.60E-08	1.20E-08	2.50E-08	2.00E-08	1.60E-08	3.00E-08	1.80E-08	2.10E-08	1.10E-08

*<https://arthritis-research.biomedcentral.com/articles/10.1186/ar3295>

FIG. 54E

FIG. 54B(i)




FIG. 54B(ii)




FIG. 54D(i)




FIG. S4D(i)





FIG. 55



Compound	EC50-SEAP
Human rIL-18	0.0044 ng/mL
FUSE500	0.0056 ng/mL
Human rTNFα	N/A
FUSE874 (L)	0.053 ng/mL
FUSE875 (5L)	0.1103 ng/mL
FUSE876 (10L)	0.1258 ng/mL
FUSE758 (15MM)	1.689 ng/mL
FUSE756 (35L)	3.257 ng/mL
FUSE499 (pp)	62.14 ng/mL




FIG. 56A




FIG. 56B






FIG. 56C




Compound	EC50-SEAP
Human rIL-18	6.7 pg/mL
Human rTNFα	N/A
FUSE888	>1000000 pg/ml
FUSE888 + GB	5900 pg/ml

FIG. 56D




Compound	EC50-SEAP
Human rIL-18	6.7 pg/mL
Human rTNFα	N/A
FUSE889	>1000000 pg/ml
FUSE889 + GB	2083 pg/ml

FIG. 56E




Compound	EC50-SEAP
Human rIL-18	6.7 pg/mL
Human rTNFα	N/A
FUSE890	>1000000 pg/ml
FUSE890 + GB	4000 pg/ml

FIG. 56F



Compound	EC50-SEAP
Human rIL-18	6.7 pg/mL
Human rTNFα	N/A
FUSE891	113000 pg/ml
FUSE891 + GB	670 pg/ml

FIG. 56G



Compound	EC50-SEAP
Human rIL-18	6.7 pg/mL
Human rTNFα	N/A
FUSE892	210000 pg/ml
FUSE892 + GB	970 pg/ml

FIG. 56H




FIG. 57A




FIG. 57B









FIG. 59A

	Yield
FUSE-211	360 mg/L
FUSE-393	458 mg/L
FUSE-394	455 mg/L
FUSE-489	253 mg/L
FUSE-497	213 mg/L
FUSE-498	117 mg/L

FIG. 59B

	Tm
FUSE-210	70.5°C
FUSE-211	70.4°C
FUSE-394	70.6°C

FIG. 60A



Jurkat cell	FUSE393	FUSE394
Binding EC50 (Kd)	3.342 nM	10.60 nM

FIG. 60B






FIG. 60C




Human pan T cell	FUSE393	FUSE394
Binding EC50 (Kd)	4.447 nM	10.48 nM

FIG. 60D




Cyno pan T cell	FUSE393	FUSE394
Binding EC50 (Kd)	3.038 nM	7.465 nM

FIG. 61A




	FUSE393	FUSE394	FUSE211
Binding EC50 (nM)	16.34	6.100	0.19

FIG. 61B




	FUSE393	FUSE394	FUSE211
Binding EC50 (nM)	26.47	19.49	0.55

FIG. 61C



	FUSE393	FUSE394	FUSE211
Binding EC50 (nM)	280.7	154.4	0.45

FIG. 61D



	FUSE393	FUSE394	FUSE211
Binding EC50 (nM)	288.4	69.7	0.40

MDA-MB-231 ROR1-KO






FIG. 61E






FIG. 62B

Loading Sample ID	KD (M)	kon(1/Ms)	kdis(1/s)
FUSE211	1.70E-08	1.35E+05	2.29E-03
FUSE393	2.18E-08	2.15E+04	4.68E-04
FUSE394	5.69E-08	2.87E+04	1.63E-03

FIG. 62D




FIG. 62A






FIG. 62C

FUSE112



FUSE453



Loading Sample ID	KD (M)	kon(1/Ms)	kdis(1/s)
FUSE112-2	4.24E-08	4.31E+04	1.83E-03
FUSE453	BLC	BLC	BLC

FIG. 62G




FIG. 62H




FIG. 62I

Loading Sample ID	KD (M)	kon(1/Ms)	kdis(1/s)
FUSE179-2	3.60E-08	4.82E+04	1.74E-03
FUSE454	BLC	BLC	BLC

FIG. 62J




FIG. 63A




FIG. 63B




FIG. 63C

Test article/Donor	EC ₅₀ (pM)
FUSE211/1	121.2
FUSE211/2	92.8
FUSE211/3	111.6
FUSE393/1	102.5
FUSE393/2	86.4
FUSE393/3	137.0
FUSE394/1	79.4
FUSE394/2	75.6
FUSE394/3	89.11

FIG. 63D




FIG. 63E




FIG. 63F




FIG. 63G

Test article/Donor	EC ₅₀ (pM)
FUSE211/1	5665*
FUSE211/2	2675*
FUSE211/3	5184*
FUSE393/1	6292
FUSE393/2	3038
FUSE393/3	3202
FUSE394/1	1471
FUSE394/2	1805
FUSE394/3	2544

FIG. 63H




FIG. 63I




FIG. 63J




FIG. 63K




FIG. 63L




FIG. 63M




FIG. 63N

Test article/assay	EC ₅₀ (pM)
FUSE277/killing	7.8
FUSE394/killing	122.6
FUSE277/IFN γ	16.0
FUSE394/IFN γ	3221

FIG. 63O




FIG. 63P




FIG. 63Q




FIG. 63R




FIG. 63S




FIG. 63T




FIG. 63U




FIG. 63V




FIG. 64A




FIG. 64B




FIG. 64C




FIG. 65A

FIG. 65B

FIG. 65C

FIG. 65D

FIG. 65E

Test article/Cell line	FUSE-277 EC ₅₀ (pM)	FUSE-211 EC ₅₀ (pM)	FUSE-393 EC ₅₀ (pM)	FUSE-394 EC ₅₀ (pM)
NCCIT	0.8	90.6	106.1	77.9
MDA-MB-231	2.1	111.6	137.0	89.1
NCI-H1975	0.8	133.3	169.0	123.1
DU-145	4.5	168.3	219.2	159.0
T-47D	NA	NA	NA	NA

FIG. 65F




FIG. 65G

FIG. 65H

FIG. 65I

FIG. 65J

FIG. 65K

Test article/Cell line	FUSE-277 EC ₅₀ (pM)	FUSE-211 EC ₅₀ (pM)	FUSE-393 EC ₅₀ (pM)	FUSE-394 EC ₅₀ (pM)
NCCIT	13.08	5327	2572	1943
MDA-MB-231	11.67	5184	3202	2544
NCI-H1975	12.3	5274	5893	3507
DU-145	14.2	4288	3420	2976
T-47D	NA	NA	NA	NA

FIG. 65L




FIG. 65M




FIG. 66F

Test article/Cell line	FUSE-277 EC ₅₀ (pM)	FUSE-211 EC ₅₀ (pM)	FUSE-393 EC ₅₀ (pM)	FUSE-394 EC ₅₀ (pM)
MDA-MB-231++	3.4	70.9	91.4	64.8
MDA-MB-231+	3.2	83.1	109.4	79.2
MDA-MB-231	2.0	111.6	137.0	79.8
MDA-MB-231-low	1.8	162.8	168.9	133.4
MDA-MB-231-KO	NA	NA	NA	NA




FIG. 66L




FIG. 66M






FIG. 66N



Test article/Donor	EC50 CD69 (nM)	EC50 CD25 (nM)
FUSE399	0.2	0.2
FUSE211	4.6	4.9
FUSE393	8.2	12.5
FUSE394	4.1	6.9

FIG. 67C




FIG. 67D




FIG. 67E




FIG. 67F






FIG. 67G



		Cirmtuzumab	FUSE-394	FUSE-211	FUSE-394	FUSE-211
Parameter	Unit	5 mg/kg			0.5 mg/kg	
t1/2Alpha	h	5.49	4.69	2.68	7.14	1.61
t1/2Beta	h	203.7	114.1	153.9	165.4	184.3
C0	ng/ml	77125	97093	109201	8566	12342
CL	(µg)/(ng/ml)/h	8.30E-06	1.14E-05	1.17E-05	9.71E-06	9.38E-06
CL2	(µg)/(ng/ml)/h	7.28E-05	6.37E-05	0.000146	5.14E-05	0.000229
AUC 0-t	ng/ml*h	6857566	6783473	5730617	670181	641843
AUC 0-inf	ng/ml*h	12054877	8747928	8529634	1030369	1066185

FIG. 68C




FIG. 69A







FIG. 69B






FIG. 70A




FIG. 70B




FIG. 70C




FIG. 70D




FIG. 70E

Serial killing




FIG. 71A

Average of 4
donors except 399
= 2 donors







FIG. 71B

FIG. 72



Name	EC ₅₀ (nM)	Max MFI
FUSE-179-2	2.04	4905.00
FUSE559	2.31	7599.00
FUSE524	2.74	7084.00
Anti-HEL (hIgG1)	N/A	N/A



Method	Ligand	Immobilized Level (RU)	Analyte	Analyte Conc.	1:1 binding ka (1/Ms)	kd (1/s)	KD (M)
CM5	ROR1	4400	FUSE-179-2	200nM	1.44E+05	1.06E-03	7.38E-09
CM5	ROR1	4400	FUSE559	200nM	3.01E+05	7.70E-04	2.56E-09

EC50 FACS 608 – ROR1 and CD3





FIG. 75A Donor 2 T cell with MDA-MB-231 cell at 24 hour





FIG. 75B






FIG. 76A




FIG. 76B




FIG. 76C




FIG. 76D

Cytotoxicity - 24 hour		FUSE399	FUSE608
MDA-MB-231 cell	Emax(%)	67.37	72.5
MDA-MB-231 cell	EC50 (pM)	22.31	51.96
MDA-MB-231 cell	AUC	6690712	7191406
NCI-H1975 cell	Emax(%)	60.16	63.51
NCI-H1975 cell	EC50 (pM)	24.62	50.31
NCI-H1975 cell	AUC	5958735	6308421
Jeko-1 cell	Emax(%)	66.02	68.57
Jeko-1 cell	EC50 (pM)	26.49	49.39
Jeko-1 cell	AUC	6526792	6775067

FIG. 76I




FIG. 76E




FIG. 76F




FIG. 76G




FIG. 76H

IFN gamma release - 24 hours		FUSE399	FUSE608
MDA-MB-231 cell	Emax(pg/mL)	18026	16449
MDA-MB-231 cell	EC50 (pM)	144.2	4467
MDA-MB-231 cell	AUC	54219	26506
NCI-H1975 cell	Emax(pg/mL)	13987	12259
NCI-H1975 cell	EC50 (pM)	155.6	4638
NCI-H1975 cell	AUC	20632	41884
Jeko-1 cell	Emax(pg/mL)	17267	15726
Jeko-1 cell	EC50 (pM)	189.2	4438
Jeko-1 cell	AUC	51370	24826

FIG. 76J




FIG. 77A




FIG. 77B




FIG. 77C




FIG. 77D




FIG. 77E

72-hour assay	FUSE399	FUSE608
PD-1 MFI Emax	43710	31323
PD-1 MFI EC50 (pM)	162.7	1940
PD-1 MFI AUC	4333982454	2798697290
CD69 MFI Emax	23845	21785
CD69 MFI EC50 (pM)	90.35	3275
CD69 MFI AUC	2347779620	1825955348
TIGIT MFI Emax	14459	13262
TIGIT MFI EC50 (pM)	68.14	1829
TIGIT MFI AUC	1401162867	1231187292

FIG. 77F




FIG. 78A




FIG. 78C




FIG. 78B




FIG. 79A




FIG. 79B

FIG. 79C 1:1 mixture MDA-MB-231 RFP + T47D-eGFP
Viability of ROR1+ MDA-MB-231 RFP




FIG. 79D 1:1 mixture MDA-MB-231 RFP + T47D-eGFP
Viability of ROR1neg T47D eGFP




FIG. 80A MDA-MB-231 in humanized NSG mice
MDA-MB-231 mouse model efficacy assesment




FIG. 80B MDA-MB-231 mouse model survival assessment

